JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
 QUICK SEARCH:   [advanced]


     


J Am Coll Cardiol, 2005; 45:1925-1931, doi:10.1016/j.jacc.2005.03.041
© 2005 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pfützner, A.
Right arrow Articles by Forst, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pfützner, A.
Right arrow Articles by Forst, T.

CLINICAL RESEARCH: CLINICAL TRIAL

Improvement of Cardiovascular Risk Markers by Pioglitazone Is Independent From Glycemic Control

Results From the Pioneer Study

Andreas Pfützner, MD, PhD*,{dagger},*, Nikolaus Marx, MD{ddagger}, Georg Lübben, MD§, Matthias Langenfeld, MD*, Daniel Walcher, MD{ddagger}, Thomas Konrad, MD|| and Thomas Forst, MD*

* IKFE—Institute for Clinical Research and Development, Mainz, Germany
{dagger} University of Applied Sciences, Rheinbach, Germany
{ddagger} University Hospital, Ulm, Germany
§ Takeda Pharma GmbH, Aachen, Germany
|| ISF—Institute for Metabolic Research, Frankfurt, Germany

Manuscript received October 12, 2004; revised manuscript received February 14, 2005, accepted March 10, 2005.

* Reprint requests and correspondence: Dr. Andreas Pfützner, Institute for Clinical Research and Development, Parcusstr. 8, D-55116 Mainz, Germany. (Email: AndreasP{at}ikfe.de).

OBJECTIVES: This study was performed to assess whether the anti-inflammatory and antiatherogenic effects of pioglitazone suggested by animal experiments are reproducible in man and independent from improvements in metabolic control.

BACKGROUND: Type 2 diabetes is associated with increased cardiovascular risk.

METHODS: A total of 192 patients were enrolled into a six-month, prospective, open-label, controlled clinical study. They were randomized to receive either pioglitazone (45 mg) or glimepiride (1 to 6 mg, with the intent to optimize therapy). Biochemical and clinical markers to assess therapeutic effects included HbA1c, fasting glucose, insulin, adiponectin, lipids, high-sensitivity C-reactive protein (hsCRP), intracellular adhesion molecule, vascular cell adhesion molecule, vascular endothelial growth factor, fibrinogen, von Willebrand factor, matrix metalloproteinase (MMP)-9, monocyte chemoattractant protein (MCP)-1, soluble CD40 ligand, and carotid intima-media thickness (IMT).

RESULTS: The study was completed by 173 patients (66 female, 107 male; age [± SD]: 63 ± 8 years; disease duration: 7.2 ± 7.2 years; HbA1c: 7.5 ± 0.9%; pioglitazone arm: 89 patients). A comparable reduction in HbA1c was seen in both groups (p < 0.001). In the pioglitazone group, reductions were observed for glucose (p < 0.001 vs. glimepiride group at end point), insulin (p < 0.001), low-density lipoprotein/high-density lipoprotein ratio (p < 0.001), hsCRP (p < 0.05), MMP-9 (p < 0.05), MCP-1 (p < 0.05), and carotid IMT (p < 0.001), and an increase was seen in high-density lipoprotein (p < 0.001) and adiponectin (p < 0.001). Spearman ranks analysis revealed only one correlation between the reduction in cardiovascular risk parameters and the improvement in the metabolic parameters (MMP-9 and fasting blood glucose, p < 0.05)

CONCLUSIONS: This prospective study gives evidence of an anti-inflammatory and antiatherogenic effect of pioglitazone versus glimepiride. This effect is independent from blood glucose control and may be attributed to peroxisome proliferator-activated receptor gamma activation.

Abbreviations and Acronyms
  HDL = high-density lipoprotein
  hsCRP = high-sensitivity C-reactive protein
  ICAM = intracellular adhesion molecule
  IMT = intima-media thickness
  LDL = low-density lipoprotein
  MCP = monocyte chemoattractant protein
  MMP = matrix metalloproteinase
  PPAR{gamma} = peroxisome proliferator-activated receptor gamma
  PROactive = Prospective Pioglitazone Clinical Trial in Macrovascular Events
  sCD40L = soluble CD40 ligand
  TZD = thiazolidinedione
  VCAM = vascular cell adhesion molecule
  VEGF = vascular endothelial growth factor




This article has been cited by other articles:


Home page
J Clin PharmacolHome page
D. F. Lehmann and B. B. Lohray
A Lesson in Moderation: Applying Pharmacodynamics to Clarify the Relationship Between Thiazolidinediones and Adverse Vascular Outcomes in Type 2 Diabetes
J. Clin. Pharmacol., August 1, 2008; 48(8): 999 - 1002.
[Full Text] [PDF]


Home page
Diabetes CareHome page
A. Sultan, A. Avignon, F. Galtier, C. Piot, D. Mariano-Goulart, A. M. Dupuy, and J. P. Cristol
Osteoprotegerin, Thiazolidinediones Treatment, and Silent Myocardial Ischemia in Type 2 Diabetic Patients
Diabetes Care, March 1, 2008; 31(3): 593 - 595.
[Full Text] [PDF]


Home page
CJASNHome page
S. Ogawa, T. Mori, K. Nako, T. Ishizuka, and S. Ito
Reduced Albuminuria with Sarpogrelate Is Accompanied by a Decrease in Monocyte Chemoattractant Protein-1 Levels in Type 2 Diabetes
Clin. J. Am. Soc. Nephrol., March 1, 2008; 3(2): 362 - 368.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. K. Ohman, Y. Shen, C. I. Obimba, A. P. Wright, M. Warnock, D. A. Lawrence, and D. T. Eitzman
Visceral Adipose Tissue Inflammation Accelerates Atherosclerosis in Apolipoprotein E-Deficient Mice
Circulation, February 12, 2008; 117(6): 798 - 805.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
M. Fernandez, C. Triplitt, E. Wajcberg, A. A. Sriwijilkamol, N. Musi, K. Cusi, R. DeFronzo, and E. Cersosimo
Addition of Pioglitazone and Ramipril to Intensive Insulin Therapy in Type 2 Diabetic Patients Improves Vascular Dysfunction by Different Mechanisms
Diabetes Care, January 1, 2008; 31(1): 121 - 127.
[Abstract] [Full Text] [PDF]


Home page
Vasc MedHome page
A. S. Kelly, A. M. Thelen, D. R. Kaiser, J. M. Gonzalez-Campoy, and A. J. Bank
Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus
Vascular Medicine, November 1, 2007; 12(4): 311 - 318.
[Abstract] [PDF]


Home page
DiabetesHome page
C. Werner, C. H. Kamani, C. Gensch, M. Bohm, and U. Laufs
The Peroxisome Proliferator Activated Receptor-{gamma} Agonist Pioglitazone Increases Number and Function of Endothelial Progenitor Cells in Patients With Coronary Artery Disease and Normal Glucose Tolerance
Diabetes, October 1, 2007; 56(10): 2609 - 2615.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
A. M. Lincoff, K. Wolski, S. J. Nicholls, and S. E. Nissen
Pioglitazone and Risk of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Trials
JAMA, September 12, 2007; 298(10): 1180 - 1188.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
C. V. Leier and G. J. Haas
Diabetes and Heart Failure: The Role of Thiazolidinediones in Managing These Partners in Crime
J. Am. Coll. Cardiol., July 3, 2007; 50(1): 37 - 39.
[Full Text] [PDF]


Home page
StrokeHome page
J. F. Arenillas, M. A. Moro, and A. Davalos
The Metabolic Syndrome and Stroke: Potential Treatment Approaches
Stroke, July 1, 2007; 38(7): 2196 - 2203.
[Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
E. Ruiz, S. Redondo, A. Gordillo-Moscoso, and T. Tejerina
Pioglitazone Induces Apoptosis in Human Vascular Smooth Muscle Cells from Diabetic Patients Involving the Transforming Growth Factor-beta/Activin Receptor-Like Kinase-4/5/7/Smad2 Signaling Pathway
J. Pharmacol. Exp. Ther., May 1, 2007; 321(2): 431 - 438.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
E. Wajcberg, A. Sriwijitkamol, N. Musi, R. A. DeFronzo, and E. Cersosimo
Relationship between Vascular Reactivity and Lipids in Mexican-Americans with Type 2 Diabetes Treated with Pioglitazone
J. Clin. Endocrinol. Metab., April 1, 2007; 92(4): 1256 - 1262.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
J. T. Crossno Jr., C. V. Garat, J. E. B. Reusch, K. G. Morris, E. C. Dempsey, I. F. McMurtry, K. R. Stenmark, and D. J. Klemm
Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling
Am J Physiol Lung Cell Mol Physiol, April 1, 2007; 292(4): L885 - L897.
[Abstract] [Full Text] [PDF]


Home page
British Journal of Diabetes & Vascular DiseaseHome page
A. H Barnett
Summarising the use of thiazolidinediones with insulin
The British Journal of Diabetes & Vascular Disease, March 1, 2007; 7(2): 75 - 80.
[Abstract] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
A. M. Sharma and B. Staels
Peroxisome Proliferator-Activated Receptor {gamma} and Adipose Tissue--Understanding Obesity-Related Changes in Regulation of Lipid and Glucose Metabolism
J. Clin. Endocrinol. Metab., February 1, 2007; 92(2): 386 - 395.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. D. Brown and J. Plutzky
Peroxisome Proliferator Activated Receptors as Transcriptional Nodal Points and Therapeutic Targets
Circulation, January 30, 2007; 115(4): 518 - 533.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
M. Hanefeld, N. Marx, A. Pfutzner, W. Baurecht, G. Lubben, E. Karagiannis, U. Stier, and T. Forst
Anti-Inflammatory Effects of Pioglitazone and/or Simvastatin in High Cardiovascular Risk Patients With Elevated High Sensitivity C-Reactive Protein: The PIOSTAT Study
J. Am. Coll. Cardiol., January 23, 2007; 49(3): 290 - 297.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
L. Michalik, J. Auwerx, J. P. Berger, V. K. Chatterjee, C. K. Glass, F. J. Gonzalez, P. A. Grimaldi, T. Kadowaki, M. A. Lazar, S. O'Rahilly, et al.
International Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors
Pharmacol. Rev., December 1, 2006; 58(4): 726 - 741.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
A. J. Gilde, J.-C. Fruchart, and B. Staels
Peroxisome Proliferator-Activated Receptors at the Crossroads of Obesity, Diabetes, and Cardiovascular Disease
J. Am. Coll. Cardiol., October 27, 2006; 48(9_Suppl_A): A24 - A32.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
S. Ahmed, C. P. Cannon, S. A. Murphy, and E. Braunwald
Acute coronary syndromes and diabetes: is intensive lipid lowering beneficial? Results of the PROVE IT-TIMI 22 trial
Eur. Heart J., October 1, 2006; 27(19): 2323 - 2329.
[Abstract] [Full Text] [PDF]


Home page
British Journal of Diabetes & Vascular DiseaseHome page
I. W Campbell
The role of metformin and pioglitazone in early combination treatment of type 2 diabetes mellitus
The British Journal of Diabetes & Vascular Disease, September 1, 2006; 6(5): 207 - 215.
[Abstract] [PDF]


Home page
StrokeHome page
H. Yokoyama, N. Katakami, and Y. Yamasaki
Recent Advances of Intervention to Inhibit Progression of Carotid Intima-Media Thickness in Patients With Type 2 Diabetes Mellitus
Stroke, September 1, 2006; 37(9): 2420 - 2427.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
Z. T. Bloomgarden
Third Annual World Congress on the Insulin Resistance Syndrome: Atherothrombotic disease
Diabetes Care, August 1, 2006; 29(8): 1973 - 1980.
[Full Text] [PDF]


Home page
Diabetes CareHome page
H. Sourij, R. Zweiker, and T. C. Wascher
Effects of Pioglitazone on Endothelial Function, Insulin Sensitivity, and Glucose Control in Subjects With Coronary Artery Disease and New-Onset Type 2 Diabetes
Diabetes Care, May 1, 2006; 29(5): 1039 - 1045.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
M. Hermann and F. Ruschitzka
Novel anti-inflammatory drugs in hypertension
Nephrol. Dial. Transplant., April 1, 2006; 21(4): 859 - 864.
[Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
F. Meisner, D. Walcher, F. Gizard, X. Kapfer, R. Huber, A. Noak, L. Sunder-Plassmann, H. Bach, C. Haug, M. Bachem, et al.
Effect of Rosiglitazone Treatment on Plaque Inflammation and Collagen Content in Nondiabetic Patients: Data From a Randomized Placebo-Controlled Trial
Arterioscler. Thromb. Vasc. Biol., April 1, 2006; 26(4): 845 - 850.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
P. O. Szapary, L. T. Bloedon, F. F. Samaha, D. Duffy, M. L. Wolfe, D. Soffer, M. P. Reilly, J. Chittams, and D. J. Rader
Effects of Pioglitazone on Lipoproteins, Inflammatory Markers, and Adipokines in Nondiabetic Patients with Metabolic Syndrome
Arterioscler. Thromb. Vasc. Biol., January 1, 2006; 26(1): 182 - 188.
[Abstract] [Full Text] [PDF]




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2005 by the American College of Cardiology Foundation.